# US 6,416,958 B2 · Selective apoptosis of neoplastic cells by an HLA-DR specific monoclonal antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,416,958 B2
- Document ID: US6416958B2
- Status: Granted
- Kind: B2
- Application number: 09/929,209
- Filed: 2001-08-13
- Published: 2001-12-20
- Granted: 2002-07-09
- Earliest claimed: 1998-08-28
- Assignees: Dendreon Corporation
- Inventors: Damir Vidovic; Reiner Laus
- Web page: https://patentgrep.com/patent/US6416958B2

## CPC

- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Anti-human major histocompatibility complex (MHC) class II, HLA-DR-specific monoclonal antibodies which can induce apoptosis of HLA-DR positive cells are disclosed. The antibodies are used to specifically eliminate HLA-DR antigen positive tumor cells by cross-linking of HLA-DR. Also disclosed are methods for treating cancer using such antibodies, and compositions containing them.

## Claims

### Claim 1

A method of triggering apoptosis, comprising
administering to a subject, a therapeutically effective amount of an anti-HLA-DR antibody effective to stimulate apoptosis in HLA-DR-expressing tumor cells.

### Claim 2 (depends on 1)

The method of claim 1 wherein the therapeutic outcome of the subject is improved following said administration.

### Claim 3 (depends on 2)

The method of treating cancer according to claim 2 wherein said cancer involves HLA-DR expressing cells and is selected from the group consisting of plasmacytoma/multiple myeloma, Hodgkin's lymphomas, non-Hodgkin's lymphomas and B cell leukemias.

### Claim 4 (depends on 2)

The method of claim 2 wherein the therapeutic anti-HLA-DR antibody is administered intravenously (IV).

### Claim 5 (depends on 2)

The method of claim 2 wherein the therapeutic anti-HLA-DR antibody is administered parenterally.